Patents Assigned to Biomedical Research Models, Inc.
-
Patent number: 9566325Abstract: The invention provides methods and kits for inducing a therapeutic immunity in animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2. In particular, the invention provides a method of treating animals with an established HSV-2 infection by administering a therapeutic vaccine comprising a priming dose of a nucleic acid encoding an HSV-2 antigen, an initial or first boosting dose comprising the protein form of the antigen encapsulated in liposomes, and one or more subsequent boosting doses comprising both the nucleic acid encoding the HSV-2 antigen and the liposomal-encapsulated protein antigen.Type: GrantFiled: January 7, 2014Date of Patent: February 14, 2017Assignee: BIOMEDICAL RESEARCH MODELS, INC.Inventors: Kejian Yang, Dennis L. Guberski
-
Publication number: 20140193483Abstract: The invention provides methods and kits for inducing a therapeutic immunity in animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2. In particular, the invention provides a method of treating animals with an established HSV-2 infection by administering a therapeutic vaccine comprising a priming dose of a nucleic acid encoding an HSV-2 antigen, an initial or first boosting dose comprising the protein form of the antigen encapsulated in liposomes, and one or more subsequent boosting doses comprising both the nucleic acid encoding the HSV-2 antigen and the liposomal-encapsulated protein antigen.Type: ApplicationFiled: January 7, 2014Publication date: July 10, 2014Applicant: Biomedical Research Models, Inc.Inventors: Kejian YANG, Dennis L. Guberski
-
Publication number: 20120027841Abstract: The invention provides methods and kits for immunizing animals (e.g. mammals) against viral antigens, including herpes-simplex virus type 2. The protective immune response elicited by the methods and kits of the invention is characterized by robust humoral, cellular, and mucosal immunity. In particular, the invention provides a heterologous immunization method comprising a priming DNA vaccine encoding an antigen and a boosting protein vaccine, in which the protein form of the antigen is encapsulated in liposomes. Methods of preventing primary acute, latent and recurrent viral infections, such as that caused by HSV-2 virus, and methods of providing passive protective immunity against a viral pathogen such as HSV-2 virus to a mammal are also disclosed.Type: ApplicationFiled: March 9, 2011Publication date: February 2, 2012Applicant: Biomedical Research Models, Inc.Inventors: Kejian YANG, Dennis L. Guberski
-
Publication number: 20080267963Abstract: The invention relates to methods and reagents for immunizing and treating individual with cancer to elicit specific cellular and humoral immune-responses against specific cancer cell surface antigens, including those cancer cell surface antigens expressed only in cancer cells and in non-cancer cells normally located in one or more immune-privileged sites or tissues of the individual. The invention provides methods of using specifically prepared immunogen in fresh or lyophilized liposome, proper routes of administration of the immunogen, proper doses of the immunogen, and specific combinations of heterologous immunization including DNA priming in one administration route followed by liposome-mediated protein antigen boost in a different route to tailor the immune responses in respects of enhancing cell mediated immune response, cytokine secretion, humoral immune response, especially skewing T helper responses to be Th1 or a balanced Th1 and Th2 type.Type: ApplicationFiled: October 27, 2005Publication date: October 30, 2008Applicant: Biomedical Research Model, Inc.Inventors: Edward H. Kislauskis, Kejian Yang, Barbara J. Whalen
-
Publication number: 20060035853Abstract: The invention relates to methods and reagents for immunizing animals to elicit specific cellular and humoral immune-responses against specific antigens, such as viral antigens, including HBsAg antigen. The invention provides methods of using specifically prepared immunogen in fresh or lyophilized liposome, proper routes of administration of the immunogen, proper doses of the immunogen, and specific combinations of heterologous immunization including DNA priming in one administration route followed by liposome-mediated protein antigen boost in a different route to tailor the immune responses in respects of enhancing cell mediated immune response, cytokine secretion, humoral immune response, immune protection and selective skewing of T helper responses to be Th1, Th2, or a mixed or balanced Th response.Type: ApplicationFiled: January 7, 2005Publication date: February 16, 2006Applicants: Biomedical Research Models, Inc., Oral Vaccine Technologies , Inc,Inventors: Kejian Yang, Barbara Whalen, Edward Kislauskis, Dennis Guberski
-
Patent number: 6939538Abstract: An extended release analgesic for controlling pain comprised of an opioid or non-opioid analgesic drug ionically bound to hyaluronic acid, poly-?-glutamic acid or other ionic polymers, and injected into a body either subcutaneously, intramuscularly or intraperitoneally, utilizing counter-ions of different valences to control the rate of release into the body.Type: GrantFiled: April 10, 2003Date of Patent: September 6, 2005Assignee: Biomedical Research Models, Inc.Inventors: Albert Prescott, Edward Kislauskis, Dennis L. Guberski